Inventors:
Robert A. Brodsky - Brooklandville MD, US
Richard J. Jones - Baltimore MD, US
Richard F. Ambinder - Baltimore MD, US
Assignee:
Accentia Biopharmaceuticals, Inc. - Tampa FL
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 31/675, A61P 35/00, A61P 37/06
Abstract:
The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug, either alone, or in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.